P1.04-32 Phase I/Ii Study of the A2AR Antagonist NIR178 (PBF-509), an Oral Immunotherapy, in Patients (Pts) With Advanced NSCLC

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.747

Related search